Impact of complement inhibitor therapy on ICU/IMC care of generalized myasthenia gravis patients in Germany - a retrospective analysis

Recruiting

• Conditions: G70.0; Myasthenia gravis

• Registration Number: DRKS00032104
• Lead Sponsor: Charité - Universitätsmedizin Berlin

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-08-08
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

AchR-Ab+ generalized myasthenia gravis (defined in this project as either serologic antibody or cell-based-assay antibody or immunohistochemic proof of complement deposits at the neuromuscular junction in a muscle biopsy)
- presence of a myasthenic crisis (MGFA V) or severe exacerbation with involvement of the pharyngeal and/or respiratory muscles (MGFA IVb) that requires treatment in ICU or IMC setting
-start of therapy with either eculizumab or ravulizumab during the myasthenic crisis or severe exacerbation (while MGFA was V or IVb)

Exclusion Criteria

- presence of a cholinergic crisis without a diagnosis of myasthenia gravis
- presence of a different myasthenic syndrome such as lambert eaton myasthenic syndrome or congenital myasthenic syndrome
- the myasthenic crisis started less than 4 weeks after thymectomy

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Percentage of patients who were discharged from ICU/IMC 6 weeks after starting the complement-inhibitor therapy.